Viatris
VTRS
$0.17 (1.33%)
1D
1W
3M
1Y
5Y
ALL
Viatris Inc. is a global healthcare company. The Company has four segments: Developed Markets, Greater China, JANZ and Emerging Markets. Developed Markets segment comprises its operations primarily in North America and Europe. Greater China segment includes its operations in China, Taiwan and Hong Kong. JANZ segment reflects its operations in Japan, Australia and New Zealand. Emerging Markets segment encompasses its presence in approximately 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as its anti-retroviral franchise. Its portfolio comprises approximately 1,400 approved molecules across a range of key therapeutic areas, including globally recognized iconic and key brands, generics, complex generics, and biosimilars. It operates approximately 40 manufacturing sites worldwide, which produces oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Reuters • 4 days ago • VTRS
US FDA sends warning letter to Viatris over India manufacturing facilityPRNewsWire • 9 days ago • VTRS
Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet RheumatologyGlobeNewsWire • 25 days ago • VTRS
Mapi Pharma is Seeking New Depot Product PartnershipsMarketBeat • 30 days ago • VTRS
2 Generic Drug Stocks Ready to Surge in 2025Reuters • about a month ago • VTRS
UK watchdog fines Viatris $1.9 mln over rule breach in Theramex probeCharts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.